Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Inovio Investors Should Watch This Video Before Losing Their Shirts

Yesterday we published an article about Inovio Pharmaceuticals, Inc. (NASDAQ:INO) that summarized Citron Research’s Inovio short campaign. Personally I find the methods used by activist short sellers tasteless. However, I think short selling is an essential part of the financial markets. As long as they aren’t intentionally spreading lies and are merely expressing their skepticism on a hyped up company, I have no problem sharing their opinions on our website. That doesn’t imply that I agree with every opinion shared on our website.

I want to disclose that I have no positions in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and I have no business relationships with Citron. I try to be an objective investor and make the right decisions when it comes to buying, selling, or shorting a stock. I share my personal stock picks in Insider Monkey’s monthly newsletter and my portfolio of stock picks returned 72% over the last 3+ years and beat the S&P 500 ETFs by 44 percentage points. Now and then I was wrong about some stocks, but most of the time I was right.

I also predicted the coronavirus recession in February and warned our readers in this article. In early March when the collapse in the stock market was so obvious, I warned our readers once again in this article. My stock picks beat the market before the coronavirus crash, during the coronavirus crash, and after the coronavirus crash.

This weekend I interviewed Sio Capital’s Michael Castor (pictured above) who also correctly predicted the coronavirus pandemic when most investors were dismissing the threat. S&P 500 Index lost nearly 20% during the first quarter, yet Castor’s healthcare focused hedge fund Sio Capital returned more than 7% during the same period.

We asked Michael Castor to share views on Gilead Sciences Inc (NASDAQ:GILD) as well as COVID-19 vaccine stocks such as Moderna Inc (NASDAQ:MRNA). If you are an Inovio Pharmaceuticals, Inc. (NASDAQ:INO) investor and betting a large chunk of your savings on this stock, you have to watch the video below  (if you don’t have time for the entire video, skip to the 21:40 minute mark):

Michael Castor is shorting Moderna Inc (NASDAQ:MRNA) because its “quick” vaccine development approach is riskier than the more reliable vaccine development approaches pursued by 70 different companies elsewhere. I didn’t ask Castor about his views on Inovio, but I doubt that his response would be positive.

I have nothing against Inovio investors but I believe the probability of higher returns at its currently elevated stock price is much lower than the probability of lower returns in the next 12 months.

Disclosure: No positions in Moderna Inc (NASDAQ:MRNA), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), and Gilead Sciences (NASDAQ:GILD). We recommended a short position in MRNA and I am planning to initiate a short position too. This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.